First AI-Designed Drug Poised for FDA Approval by 2026-2027: Insilico Medicine’s IPF Candidate Leads

July 5, 2026

Oncodaily USA

Overview

The first AI-designed drug is increasingly likely to gain FDA approval between 2026 and 2027, with Insilico Medicine’s rentosertib for idiopathic pulmonary fibrosis (IPF) identified as the leading candidate. Eli Lilly’s $2.75 billion partnership with Insilico Medicine in March 2026 aims to accelerate the development of AI-designed oral therapies. This momentum suggests AI is genuinely innovating drug discovery from “identification” to “development,” potentially expediting market entry for new medicines.

In Depth

Key Findings

The prospect of the first entirely AI-designed drug receiving U.S. Food and Drug Administration (FDA) approval is now highly probable between 2026 and 2027. The leading candidate for this historic milestone is rentosertib, developed by Insilico Medicine for the treatment of idiopathic pulmonary fibrosis (IPF). This advancement represents a watershed moment, demonstrating AI’s capacity to move beyond proof-of-concept and deliver tangible medicines to patients.

Technical / Clinical Details

Insilico Medicine’s rentosertib is the pioneering drug designed by an AI-driven discovery platform, developed to target a novel, previously unaddressed target. Idiopathic pulmonary fibrosis is a debilitating, progressive lung disease characterized by scarring of lung tissue and declining respiratory function, with limited treatment options. Rentosertib emerged from AI’s analysis of vast biological data and chemical structure data to identify new target molecules and then design small-molecule compounds with optimal binding characteristics for these targets. Clinical trials have shown promising results in suppressing lung function decline and slowing disease progression in IPF patients, with a favorable safety profile reported.

Background & Context

AI drug discovery has garnered immense attention from the pharmaceutical industry due to its potential to dramatically shorten the lead compound identification period—which traditionally takes years—and reduce development costs. Insilico Medicine is one of the trailblazing companies demonstrating that AI can deliver value across both the “discovery” and “development” phases of drug creation. In March 2026, Eli Lilly entered a significant partnership with Insilico Medicine, valued at up to $2.75 billion. This collaboration, aimed at leveraging Insilico Medicine’s AI platform for developing AI-designed oral therapies in specific disease areas, reflects the increasing integration of AI technology into the pipelines of major pharmaceutical corporations.

Strategic Significance & Outlook

FDA approval of rentosertib would exponentially enhance the credibility and practical utility of AI drug discovery. It would serve as powerful validation that AI is not merely a research tool but is capable of generating therapeutics that genuinely impact medical practice. This approval is anticipated to accelerate further investment in AI drug discovery companies and stimulate competition in the development of AI-designed drugs for other disease areas. In the future, AI may become indispensable across all stages of the drug discovery process, ushering in a new era of pharmaceutical development where more innovative therapies reach patients more rapidly.

Source: https://oncodaily.com/techology/ai531721

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.